Kiniksa PharmaceuticalsKNSA
13F holders, Q2 2025 (June 30)2holders
0new positions
0sold out
$27.67avg. 13F price*
At the end of Q2 2025, 2 institutions reported holding Kiniksa Pharmaceuticals Ltd. (KNSA) in their 13F filings, unchanged from Q1 2025. 0 opened new positions and 0 sold out. The largest holders were Harbor Capital Advisors, Inc. ($2.0M) and Birchview Capital, LP ($830K).
- Company
- Kiniksa Pharmaceuticals Ltd.
- CUSIP
- G5269C101
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 6,802 shares sold, net −6,802 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Harbor Capital Advisors, Inc. | 0.08% | Reduce -8.7% | 70,926 | $2.0M |
| Birchview Capital, LP | 0.82% | Reduce -0.0% | 30,000 | $830K |
"% of holder's portfolio" is KNSA's weight in each manager's 13F, not the share of Kiniksa Pharmaceuticals Ltd. the manager owns.